2月17日，是移植物抗宿主病日（GVHD ...

中国青年报客户端讯（中青报·中青网记者 夏瑾）每年2月17日是移植物抗宿主病日（GVHD ...

For over a thousand people who undergo a stem cell or bone marrow transplant, survival comes at a cost: graft-versus-host disease (GvHD). 1 GvHD is a life-altering condition which affects 30 to 40 per ...

2024年12月，美国食品药物管理局（FDA）批准了Mesoblast公司的Ryoncil (remestemcell-l-rkind) ——一种同种异体骨髓间充质基质细胞（MSC）疗法，用于治疗儿科急性类固醇难治性移植物抗宿主病（GVHD），这一获批最终结束了美国长期以来没有MSC药品上市的局面。此前，包括欧洲、日本、印度和韩国在内的多个国家已经批准了自体或同种异体MSC产品。

FDA 已批准 remestemcel-L (Ryoncil) 用于治疗类固醇难治性急性移植物抗宿主病 (SR-aGVHD) 的儿科患者。 美国食品药品监督管理局（FDA）批准了 remestemcel-L-rknd ...

Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation. Leukemia. 2025;1-11.

Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the ...

Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.

Shernan Holtan, MD, has been named the recipient of 2025 Lukas D. Wartman Award. Holtan, chief of blood and marrow ...

Fred Hutch’s Phase 2 study among blood cancer patients is a “gamechanger” in preventing graft-versus-host disease after ...

A study found that injecting mesenchymal stem cells into periocular tissue effectively reduces eye inflammation without ...